Clinical Trials



A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors

Title:



A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors

Phase:



I

The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of BMS-663513 in cancer subjects with advanced and/or metastatic tumors.


To see if you are eligible for this trial, use the Cancer Center's Clinical Trials Matching Service, which is on OncoLink, the Cancer Center's information resource on the web.